These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34736749)

  • 1. Trypanocidal treatment of Chagas disease.
    Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Nov; 39(9):458-470. PubMed ID: 34736749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trypanocidal treatment of Chagas disease.
    Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Jun; ():. PubMed ID: 32527494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease.
    Jackson Y; Wyssa B; Chappuis F
    J Antimicrob Chemother; 2020 Mar; 75(3):690-696. PubMed ID: 31754690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Approaches for the Treatment of Chagas Disease.
    Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
    Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of Chagas disease chemotherapy.
    Guedes PM; Silva GK; Gutierrez FR; Silva JS
    Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on nifurtimox for treatment of Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2021 Apr; 57(4):251-263. PubMed ID: 33851689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in Chagas Disease Drug Discovery: A Review.
    Paucar R; Moreno-Viguri E; Pérez-Silanes S
    Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.
    Forsyth CJ; Hernandez S; Olmedo W; Abuhamidah A; Traina MI; Sanchez DR; Soverow J; Meymandi SK
    Clin Infect Dis; 2016 Oct; 63(8):1056-1062. PubMed ID: 27432838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and Clinical Treatment of Chagas Disease: A Review.
    Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM
    Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update in treatment of Chagas disease.
    Le Loup G; Pialoux G; Lescure FX
    Curr Opin Infect Dis; 2011 Oct; 24(5):428-34. PubMed ID: 21857512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.